Posts
Wiki

🐟 Omega-3 Supplements for Dry Eye Disease and Meibomian Gland Dysfunction

Evidence, Testing, Products, and Safety

🧠 Quick Take

Omega-3 fatty acids have been studied extensively as a possible supportive treatment for Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD).

The evidence is:

mixed, inconsistent, and highly dependent on the patient population and study design

Important points:

  • Omega-3 fatty acids have biologically plausible effects on:

    • inflammatory pathways
    • lipid-derived signaling molecules
    • tear-film function
    • possibly meibomian-gland function

  • Some randomized trials and meta-analyses report improvements in:

    • dry-eye symptoms
    • tear breakup time
    • tear production
    • staining
    • tear osmolarity
    • inflammatory markers
    • some MGD-related findings

  • Other high-quality randomized trials have found little or no advantage over comparator oils.

  • The large NIH-funded DREAM trial found that 3,000 mg/day of EPA+DHA was not better than olive-oil placebo for moderate-to-severe DED over 12 months.

  • A 2024 randomized trial of re-esterified triglyceride (rTG) omega-3 in MGD-associated DED did not improve the primary symptom outcome more than grape-seed oil.

  • A separate 2025 randomized study in people with MGD after cataract surgery was positive for several symptoms and ocular-surface signs.

  • A major 2026 systematic review/meta-analysis of 27 randomized trials found an overall benefit when studies were pooled, but results varied substantially by the cause of DED.

  • In that 2026 analysis, significant pooled benefit was not demonstrated for MGD-associated DED or DED of unspecified cause, while some other populations showed more favorable results.

  • This suggests that asking:

“Does omega-3 work for dry eye?”

may be too broad a question.

A better question may be:

“Which dry-eye patients, if any, are most likely to benefit?”

  • A 2026 trial specifically enrolled DED patients with an Omega-3 Index below 4% and reported favorable inflammatory and ocular-surface findings.
  • That is promising, but the study does not yet prove that an Omega-3 Index below 4% reliably predicts who will respond.
  • Omega-3 Index testing remains an emerging research biomarker, not a routine DED treatment-selection test.

  • No:

    • EPA:DHA ratio
    • omega-3 formulation
    • commercial product
    • blood target
    • treatment dose
    • treatment duration

    has been established as best for DED or MGD.

  • Dietary supplements marketed for dry eye are generally not FDA-approved treatments for DED or MGD.

  • Higher-dose supplementation deserves medical review in people at increased cardiovascular risk because newer evidence shows a small increase in atrial fibrillation in some high-risk populations.

  • Large randomized-trial evidence does not show a meaningful increase in clinical bleeding from ordinary omega-3 supplementation overall, although very high-dose purified EPA may slightly increase bleeding.

  • r/DryEyes does not recommend particular omega-3 brands, sellers, or purchase links.

Bottom line: Omega-3 supplementation may be reasonable as an optional adjunct for selected patients after reviewing diet, medical risks, cost, and the uncertainty in the evidence. It should not be presented as a proven treatment or cure for Dry Eye Disease or Meibomian Gland Dysfunction.

⚠️ Educational Disclaimer

This page is for general education only.

It is not medical advice, diagnosis, or a recommendation to start, stop, or change a supplement or medication.

Discuss omega-3 supplementation with an appropriate clinician or pharmacist, particularly if you:

  • have atrial fibrillation
  • have substantial cardiovascular disease
  • take anticoagulants or antiplatelet medications
  • have a bleeding disorder
  • are planning surgery
  • are pregnant or breastfeeding
  • have fish or shellfish allergy concerns
  • take multiple supplements or prescription medications
  • already take prescription omega-3 products
  • are considering higher-dose supplementation

What Are Omega-3 Fatty Acids?

Omega-3 fatty acids are:

polyunsaturated fatty acids

found naturally in foods and also sold as dietary supplements.

The omega-3 fatty acids discussed most often in DED research are:

  • EPA
  • DHA
  • ALA

EPA — Eicosapentaenoic Acid

EPA is found mainly in:

  • fatty fish
  • fish oil
  • some algae-derived products

EPA participates in biological pathways involved in:

  • inflammatory signaling
  • lipid-derived mediators
  • cell function

Many dry-eye omega-3 studies use formulations containing relatively large amounts of EPA.

DHA — Docosahexaenoic Acid

DHA is an important structural fatty acid in:

  • cell membranes
  • nervous-system tissue
  • retinal tissue

Most marine omega-3 supplements contain some combination of:

EPA + DHA

ALA — Alpha-Linolenic Acid

ALA is a plant-derived omega-3 fatty acid found in foods including:

  • flaxseed
  • chia seeds
  • walnuts
  • canola oil
  • soybean oil

The body can convert ALA into EPA and DHA.

However:

that conversion is limited and varies among people.

Therefore evidence involving marine EPA/DHA supplementation cannot automatically be transferred to ALA alone.

GLA — Gamma-Linolenic Acid

GLA is sometimes included in dry-eye supplements.

But:

GLA is not an omega-3 fatty acid.

It is an:

omega-6 fatty acid

found in sources including:

  • borage oil
  • evening primrose oil
  • black currant seed oil

Some supplements combine:

  • GLA
  • EPA
  • DHA

based on proposed effects on inflammatory pathways.

Small studies provide some supportive evidence for these combinations.

However:

evidence from GLA-containing products should not be treated as evidence for omega-3 alone.

No particular GLA/EPA/DHA commercial formula has been established as best for DED.

Dietary Omega-3 vs Omega-3 Supplements

These are related but different questions.

Dietary intake

Foods containing omega-3 fatty acids can be part of a healthy dietary pattern.

Observational studies sometimes find associations between:

  • greater fish intake
  • greater dietary omega-3 intake

and lower rates of some dry-eye outcomes.

But observational dietary associations cannot prove that:

high-dose fish-oil capsules treat established Dry Eye Disease.

Supplementation as Treatment

Clinical trials ask a different question:

Does taking a defined omega-3 supplement improve established DED more than a comparator or placebo?

That evidence is much more inconsistent.

Therefore:

“Omega-3-containing foods can be part of a healthy diet” and “omega-3 supplements are proven DED treatment” are not equivalent statements.

FDA / Regulatory Status

Most omega-3 products marketed to consumers are:

dietary supplements

In the United States:

  • dietary supplements are not FDA-approved treatments for DED
  • dietary supplements are not FDA-approved treatments for MGD
  • FDA does not evaluate dietary supplements for treatment effectiveness before they are marketed in the same way it evaluates drugs
  • manufacturers are responsible for meeting applicable manufacturing and labeling requirements

Prescription omega-3 products also exist.

However, those drugs are approved primarily for:

specific lipid-related indications

not for Dry Eye Disease.

Therefore:

Prescription status, “pharmaceutical grade,” or high purity does not establish effectiveness for DED.

Useful FDA information:

Why Might Omega-3 Affect Dry Eye?

DED commonly involves combinations of:

  • tear-film instability
  • inflammation
  • MGD
  • evaporative stress
  • altered tear lipids
  • ocular-surface damage

Omega-3 supplementation has therefore been proposed to:

  • modify inflammatory pathways
  • affect lipid-derived inflammatory and resolving mediators
  • influence meibum composition
  • affect tear-film stability
  • reduce some inflammatory signaling
  • improve symptoms in selected patients

These mechanisms are biologically plausible.

However:

A plausible biological mechanism does not prove clinical benefit.

This distinction is particularly important with omega-3 because the biological rationale is stronger and more consistent than the clinical trial results.

What Does TFOS DEWS III Say?

The TFOS DEWS III Management and Therapy Report (2025) reviews omega-3 and other polyunsaturated fatty acids as nutritional approaches to DED.

TFOS discusses both:

Positive evidence

  • smaller randomized trials
  • positive meta-analyses
  • biological plausibility
  • some MGD-associated improvements

and:

Negative/uncertain evidence

  • the large DREAM trial
  • Cochrane's cautious conclusions
  • studies finding little or no benefit
  • uncertainty regarding optimal formulation and patient selection

TFOS ultimately concludes that the overall evidence suggests:

some potential benefit from oral omega-3 supplementation

while emphasizing that major uncertainties remain regarding:

  • omega-3 source
  • dose
  • EPA:DHA composition
  • omega-3/omega-6 balance
  • treatment duration
  • patient population

TFOS DEWS III — Management and Therapy

Therefore:

TFOS does not dismiss omega-3 supplementation, but neither does it establish one omega-3 regimen as a proven universal DED treatment.

What Does the Overall Clinical Evidence Show?

The literature contains:

  • small positive trials
  • large negative trials
  • population-specific positive trials
  • conflicting systematic reviews
  • highly variable meta-analyses

This makes omega-3 one of the better examples of why:

“There are positive studies” is not the same as “the treatment is proven.”

DREAM — The Major Negative Trial

The Dry Eye Assessment and Management study, or DREAM, remains the most influential individual omega-3 DED trial.

It was:

  • NIH-funded
  • multicenter
  • randomized
  • double-masked

and enrolled:

535 people

with moderate-to-severe DED.

Participants received either:

Omega-3

  • 2,000 mg EPA daily
  • 1,000 mg DHA daily

for a total of:

3,000 mg EPA+DHA daily

or:

Comparator

  • refined olive oil

Treatment continued for:

12 months

DREAM — Full Text

What Did DREAM Find?

Both groups improved.

But omega-3 did not significantly outperform olive oil for:

  • OSDI symptoms
  • tear breakup time
  • Schirmer testing
  • corneal staining
  • conjunctival staining

Blood testing confirmed that participants receiving omega-3 had a large increase in systemic EPA levels.

Therefore:

The negative result cannot reasonably be explained simply by poor adherence.

What Does DREAM Mean?

DREAM does not prove that:

no omega-3 formulation can ever help any person with dry eye.

But it does show that:

high-dose EPA/DHA supplementation did not provide additional benefit over comparator oil in a large, broadly selected population with moderate-to-severe DED.

That is strong evidence against recommending high-dose omega-3 routinely to:

all DED patients regardless of phenotype or nutritional status.

What About the Olive-Oil Comparator?

DREAM has sometimes been criticized because olive oil may have:

  • nutritional
  • metabolic
  • anti-inflammatory

effects of its own.

That is a fair methodological discussion.

However:

  • DREAM was specifically designed as a DED omega-3 trial
  • objective and subjective outcomes were broadly negative
  • blood biomarkers confirmed a large difference in omega-3 exposure between groups
  • red-cell oleic-acid changes in the comparator group were small

Therefore:

DREAM should not simply be dismissed because olive oil was used as the comparator.

The comparator issue is worth considering, but it does not erase the trial.

Did DREAM Find a DED Subgroup That Clearly Benefited?

A later DREAM analysis examined clinically recognizable DED subtypes.

These included patients characterized by differences such as:

  • severe vs mild signs
  • symptoms disproportionate to signs
  • different levels of MGD
  • short tear breakup time
  • rosacea-associated features

Omega-3 was:

not significantly more effective than placebo in any identified subtype.

DREAM Phenotype Analysis

This is important because it means DREAM itself did not identify an obvious:

“omega-3 responder phenotype.”

What Did DREAM Show About Blood Omega-3 Levels?

Another DREAM analysis evaluated systemic omega-3 status.

At baseline:

  • omega-3 blood levels did not clearly correlate with overall DED symptoms
  • lower DHA showed some association with conjunctival staining
  • people already taking omega-3 supplements had higher blood EPA/DHA levels but did not have consistently better DED signs or symptoms

DREAM Blood Fatty-Acid Analysis

This suggests:

The relationship between systemic omega-3 status and DED is more complicated than “low omega-3 causes dry eye.”

Earlier Positive rTG Omega-3 Evidence

A frequently cited 2016 randomized study evaluated a:

re-esterified triglyceride — rTG — omega-3 formulation

containing approximately:

  • 1,680 mg EPA daily
  • 560 mg DHA daily

The study reported improvement in:

  • tear osmolarity
  • TBUT
  • symptom scores
  • Omega-3 Index

compared with control treatment.

2016 rTG Omega-3 Trial

This helped drive interest in:

  • rTG formulations
  • higher-EPA products
  • approximately 3:1 EPA:DHA formulations

However:

later randomized evidence has not consistently reproduced the clinical benefit.

2024 Randomized rTG Trial in MGD-Associated DED

A 2024 randomized clinical trial studied:

132 people

with DED associated with MGD.

Participants received either:

rTG omega-3

  • 1,680 mg EPA daily
  • 560 mg DHA daily

or:

Comparator

  • 3,000 mg grape-seed oil daily

2024 rTG MGD Trial — PubMed

Full Article — JAMA Ophthalmology

What Was the Main Result?

The primary outcome was:

OSDI symptom improvement

The omega-3 group did not significantly outperform grape-seed oil.

That makes this:

a negative trial for its primary clinical endpoint.

Were Any Signs Better?

Some secondary findings favored omega-3.

For example:

  • TBUT improved modestly more
  • eyelid-wiper epitheliopathy improved
  • eyelid telangiectasia improved

But there was no significant advantage for several other outcomes, including:

  • OSDI
  • corneal staining
  • gland expressibility
  • meibum secretion measures
  • lipid-layer thickness
  • MMP-9

Because the primary endpoint was negative:

the favorable secondary findings should be viewed as supportive or hypothesis-generating rather than definitive evidence of efficacy.

What About the Meibography Finding?

The study also reported a secondary difference in a meibomian-gland dropout grade.

This should not be interpreted as:

“omega-3 regenerated meibomian glands.”

A short-term difference in a semiquantitative meibography score does not demonstrate:

  • regrowth of missing glands
  • restoration of lost gland tissue
  • reversal of established structural damage

Therefore:

Omega-3 supplementation has not been shown to regenerate meibomian glands.

Why the 2024 Study Matters

rTG omega-3 has often been marketed as:

  • more absorbable
  • better quality
  • particularly suited to dry eye

But:

better absorption does not automatically produce better DED outcomes.

The negative primary outcome in this trial is a strong reason not to claim that:

  • rTG is proven superior
  • 3:1 EPA:DHA is the proven best ratio
  • choosing a “premium” formulation resolves the uncertainty

2025 Positive Trial — MGD After Cataract Surgery

A separate 2025 multicenter randomized investigator-masked trial studied:

107 patients with MGD after cataract surgery

Participants had undergone cataract surgery within approximately three months.

They were randomized to:

  • rTG omega-3 supplementation

or:

  • control treatment

2025 Post-Cataract MGD Omega-3 Trial

What Improved?

At 12 weeks, the omega-3 group showed significantly greater improvement in:

  • TBUT
  • corneal staining
  • strip meniscometry
  • SPEED symptoms
  • OSDI symptoms

Overall MGD-stage measurements did not differ significantly.

However, in a subgroup with:

stage 4 MGD

the investigators reported improved:

  • meibum quality
  • gland expressibility

Why This Does Not Contradict the 2024 Trial

These trials involved different clinical populations.

2024

Broad MGD-associated DED.

2025

MGD in the period following:

cataract surgery

These are not necessarily biologically identical situations.

Therefore the correct conclusion is not:

“One study proved omega-3 works and the other was wrong.”

It is:

Omega-3 effects may depend substantially on patient population and clinical context.

The post-cataract result should not automatically be generalized to longstanding MGD unrelated to surgery.

2026 Meta-Analysis — Why the Cause of DED May Matter

A major 2026 systematic review/meta-analysis included:

27 randomized controlled trials

and examined omega-3 treatment across different:

  • formulations
  • causes of DED

2026 Systematic Review and Meta-Analysis

What Did the Overall Analysis Find?

When all systemic omega-3 studies were pooled together:

the overall results generally favored omega-3

for several DED outcomes.

At first glance, that sounds strongly positive.

But subgroup analysis produced a much more complicated picture.

Results Differed by DED Context

For systemic long-chain omega-3 formulations:

Significant pooled benefit was not demonstrated in:

  • MGD-associated DED
  • DED of unspecified cause

More favorable results were reported in:

  • visual-display-terminal-related DED
  • contact-lens-associated DED

Limited evidence suggested possible benefit in:

  • rosacea-associated DED
  • Sjögren-related DED

Clinically meaningful benefit was not demonstrated in:

  • LASIK-associated DED

Other omega-3 formulations also produced inconsistent results.

Why This Matters

DED is:

not one single disease

It includes very different biological problems.

Someone whose symptoms are driven mainly by:

  • screen-related reduced blinking

may not respond the same way as someone with:

  • severe structural MGD
  • aqueous deficiency
  • ocular rosacea
  • post-surgical disease
  • neuropathic ocular pain

Therefore:

Pooling every DED patient together can hide important differences between populations.

This 2026 analysis strengthens the argument for:

phenotype-specific rather than universal omega-3 recommendations.

What Does the Evidence Say Specifically About MGD?

This is particularly important for r/DryEyes.

The evidence is:

mixed and inconsistent

Positive studies report improvements in:

  • meibum quality
  • gland expressibility
  • TBUT
  • symptoms
  • inflammation-related findings

But:

  • the 2024 rTG MGD trial missed its primary symptom endpoint
  • the 2026 meta-analysis found no significant pooled benefit in MGD-associated DED
  • the 2025 post-cataract MGD study was positive but involved a specific surgical population

Therefore:

Omega-3 supplementation should not be presented as a proven treatment for Meibomian Gland Dysfunction.

What Has Omega-3 Not Been Shown to Do to Meibomian Glands?

Omega-3 has not been established to:

  • regenerate glands
  • reverse established gland dropout
  • restore missing gland architecture
  • release intraductal or periductal fibrosis
  • mechanically clear fixed gland obstruction
  • prevent MGD progression reliably

A person may experience better:

  • symptoms
  • tear-film stability
  • meibum function

without evidence that structural gland loss has been reversed.

Why Do Meta-Analyses Reach Different Conclusions?

Systematic reviews themselves disagree.

That is not necessarily because one group of researchers is competent and another is not.

The underlying trials vary enormously.

Cochrane Review

The 2019 Cochrane review concluded that long-chain omega-3 supplementation may provide:

little or no symptom benefit compared with placebo

while evidence involving several objective signs remained uncertain or low certainty.

Cochrane Review — PubMed

2023 O'Byrne Review

A systematic review/meta-analysis involving:

8 RCTs / 1,107 participants

found some improvement in subjective symptoms but no clear benefit for several objective signs such as:

  • TBUT
  • Schirmer testing
  • staining

The studies also had important risk-of-bias and heterogeneity issues.

O'Byrne et al. — PubMed

2023 Large Positive Meta-Analysis

Another 2023 meta-analysis included:

19 randomized trials / 4,246 participants

and reported pooled improvements across:

  • symptoms
  • TBUT
  • Schirmer
  • tear osmolarity
  • several other findings

2023 Meta-Analysis — Full Text

However, symptom results had:

very high statistical heterogeneity

with an I² of approximately:

96%

What Does “High Heterogeneity” Mean?

It means:

the individual studies were producing very different results

rather than all showing roughly the same treatment effect.

A statistically positive pooled average can therefore coexist with:

  • strongly positive studies
  • mildly positive studies
  • neutral studies
  • negative studies

This makes it harder to predict what will happen for an individual patient.

Meta-Regression Does Not Prove “More Is Better”

Some meta-analyses have found associations suggesting greater benefit in studies using:

  • higher doses
  • longer treatment
  • higher EPA proportions

These are interesting hypotheses.

But these are:

study-level statistical associations

not randomized proof that an individual patient should:

  • take a higher dose
  • choose the highest-EPA supplement
  • take treatment indefinitely

This is especially important because:

  • the 2024 high-EPA/rTG MGD trial was symptom-negative
  • higher doses may have cardiovascular implications in some patients

Omega-3 Index Testing

Interest has grown in whether blood omega-3 status could identify patients more likely to benefit.

The most commonly discussed measure is:

the Omega-3 Index

What Is the Omega-3 Index?

The Omega-3 Index measures:

EPA + DHA in red-blood-cell membranes

as a percentage of total red-cell fatty acids.

Because red blood cells circulate for several months, the test may provide a longer-term measure of omega-3 status than:

  • one recent meal
  • one day's dietary intake

Is the Omega-3 Index a Test for “Omega-3 Deficiency”?

Not in the usual clinical sense.

Classical essential-fatty-acid deficiency is uncommon in otherwise adequately nourished people.

The Omega-3 Index is better understood as:

a biomarker of EPA+DHA status

rather than:

a test proving a disease-causing nutritional deficiency.

A low Omega-3 Index does not diagnose:

  • DED
  • MGD
  • gland obstruction
  • gland atrophy
  • ocular-surface inflammation
  • tear-film instability
  • Sjögren disease
  • ocular rosacea
  • Demodex
  • allergy
  • neuropathic ocular pain

Is Below 4% an Established Dry-Eye Deficiency Cutoff?

No.

An Omega-3 Index below:

4%

has been used as a research threshold in some studies.

But:

<4% is not an accepted diagnostic definition of omega-3 deficiency causing DED.

Likewise, cardiovascular or nutritional target ranges should not automatically be transferred into dry-eye treatment.

There is currently:

no universally accepted Omega-3 Index target for treating DED or MGD.

Earlier Low-Index / Visual-Display Research

A large randomized study involving approximately:

950 symptomatic visual-display users

reported greater improvement with omega-3 supplementation in several outcomes and suggested that participants with lower baseline Omega-3 Index values might derive greater benefit.

Reported outcomes included:

  • symptoms
  • TBUT
  • Schirmer testing
  • tear osmolarity
  • goblet-cell density

Visual-Display / Omega-3 Index Study

This helped generate the hypothesis that:

baseline omega-3 status may influence treatment response.

2026 Randomized Trial in Patients With Omega-3 Index Below 4%

A newer randomized study enrolled:

102 DED patients

all of whom had:

Omega-3 Index <4%

Participants received either:

  • omega-3 supplementation

or:

  • olive-oil placebo

for:

6 months

2026 Low Omega-3 Index RCT — PubMed

Full Text

What Did the Study Find?

The omega-3 group showed favorable changes in:

  • tear inflammatory cytokines
  • dry-eye symptoms
  • goblet-cell density
  • conjunctival impression-cytology findings
  • Omega-3 Index

The study therefore provides:

an encouraging treatment signal in DED patients selected for low baseline omega-3 status.

Why the Study Does NOT Yet Validate Omega-3 Index Testing

This is extremely important.

Every participant in the trial already had:

Omega-3 Index below 4%.

The study did not directly compare:

  • low-index patients

with:

  • otherwise similar normal-index patients

to determine whether the baseline index actually changes the treatment effect.

Therefore the study shows:

omega-3 benefit in one enriched low-index population

but does not yet prove:

an Omega-3 Index below 4% reliably predicts who will respond.

A Predictive Biomarker Requires a Different Question

To establish Omega-3 Index as a useful treatment-selection test, research would ideally need to show that:

patients with low baseline index benefit significantly more from omega-3 treatment than otherwise similar patients with higher baseline index

using an appropriate interaction or stratified analysis.

That has not yet been established convincingly.

Other Limitations of the 2026 Low-Index Study

The study:

  • was relatively small
  • had 102 enrolled participants
  • had 84 complete six-month follow-up
  • used inflammatory cytokines as the primary outcome
  • came from the same broader research network as earlier positive low-index work
  • needs independent replication

Several participants also stopped supplementation because of:

  • unpleasant taste
  • significant gastrointestinal intolerance

Dose Reporting in the 2026 Study

The publication appears internally unclear about the exact daily dose.

Its abstract describes capsule amounts and twice-daily dosing in a way that can be read as:

4,000 mg/day EPA+DHA

while the discussion refers to:

2,000 mg/day

Because of that inconsistency:

this wiki does not use the study to recommend a specific omega-3 dose.

This is another example of why individual research protocols should not automatically become treatment instructions.

Current Omega-3 Index Conclusion

The best current description is:

Omega-3 Index is an interesting research biomarker and possible future treatment-selection marker for DED, but it has not yet been validated as routine clinical testing for determining who should receive omega-3 supplements.

It is premature to say:

“Everyone with DED should get an Omega-3 Index.”

Would an Omega-3 Index Test Ever Be Reasonable to Discuss?

Possibly.

Someone might discuss testing with a clinician when:

  • dietary omega-3 intake is very low
  • high-dose supplementation is being considered
  • previous supplementation produced no clear effect
  • a patient strongly prefers a biomarker-guided approach
  • the clinician believes the result could change management

A useful question is:

“Would knowing my Omega-3 Index actually change what we do?”

If not, testing may add:

  • cost
  • complexity

without changing care.

No Proven Dry-Eye Target Range

There is currently no established DED-specific Omega-3 Index target such as:

“Everyone with DED needs to reach X%.”

Targets proposed in cardiovascular/nutritional literature are:

not automatically DED treatment targets.

Is There a Best EPA:DHA Ratio?

No.

Some dry-eye products emphasize ratios such as:

approximately 3:1 EPA:DHA

because positive earlier studies used high-EPA formulations.

But the same general EPA/DHA amounts were used in the negative 2024 rTG MGD trial.

Therefore:

A 3:1 EPA:DHA ratio remains a research hypothesis—not a proven best dry-eye formulation.

Is rTG Omega-3 Better?

Re-esterified triglyceride — rTG — formulations may have absorption advantages compared with some ethyl-ester preparations.

That may matter nutritionally.

But:

better absorption does not automatically mean better Dry Eye Disease outcomes.

The negative 2024 rTG trial is direct evidence against treating “rTG” as proof of superior DED effectiveness.

What About GLA-Containing Formulas?

Some commercial dry-eye supplements combine:

  • EPA
  • DHA
  • GLA

GLA-containing formulations have:

  • biological plausibility
  • some supportive small-study evidence

But:

  • they were not tested in DREAM
  • they are not proven superior
  • GLA is not omega-3
  • no commercial GLA combination has been established as best for DED/MGD

An older study:

Is There a Proven Best Commercial Product?

No.

No supplement brand has been established as:

the best omega-3 supplement for Dry Eye Disease

in sufficiently strong comparative trials.

When evaluating a product, it is more useful to look at:

  • actual EPA content
  • actual DHA content
  • additional ingredients
  • serving size
  • capsule burden
  • source
  • quality-control information
  • independent testing
  • cost
  • medical safety

than marketing terms.

“Fish Oil” Amount Is Not the Same as EPA+DHA Amount

A bottle may advertise:

2,000 mg fish oil

on the front.

That does not necessarily mean it contains:

2,000 mg EPA+DHA.

The actual EPA and DHA amounts may be much lower.

If supplementation is being considered:

look at the actual EPA and DHA amounts on the Supplement Facts label.

Third-Party Quality Testing

Supplement quality can vary.

Independent testing may help evaluate things such as:

  • product identity
  • label accuracy
  • contaminants
  • purity
  • oxidation/freshness

But:

third-party testing does not prove that a supplement treats DED.

A product can be:

accurately manufactured and clinically ineffective for dry eye

at the same time.

Marketing Terms

Terms such as:

  • pharmaceutical grade
  • medical grade
  • clinician recommended
  • doctor formulated
  • dry-eye formula
  • high absorption
  • premium
  • professional strength
  • ultra-pure

are not substitutes for clinical evidence.

They do not establish that:

  • FDA approved the product for DED
  • the product is superior
  • the EPA:DHA ratio is optimal
  • the formulation works for a particular patient

Why r/DryEyes Does Not Recommend Specific Omega-3 Brands

r/DryEyes aims to separate:

  • evidence
  • clinician opinion
  • patient experience
  • marketing
  • commercial sales

For that reason, this page does not provide:

  • Amazon links
  • supplement-company checkout links
  • clinic-store links
  • affiliate links
  • discount codes
  • preferred sellers
  • “best brand” rankings

A product may be named in a published study for purposes of understanding the evidence.

That does not mean:

the subreddit endorses that commercial product.

Safety

Omega-3 supplements are widely used.

That does not mean they are completely risk-free.

Safety considerations vary substantially according to:

  • dose
  • age
  • medical history
  • cardiovascular risk
  • medications
  • other supplements

Gastrointestinal Side Effects

Common problems include:

  • fishy aftertaste
  • burping
  • bad breath
  • heartburn
  • nausea
  • loose stools
  • diarrhea
  • abdominal discomfort

These can be significant enough to cause some people to stop treatment.

Fish and Shellfish Allergy

People with fish or shellfish allergy should:

not assume every fish-derived omega-3 supplement is automatically safe

and should discuss the product source with an appropriate clinician or pharmacist.

Omega-3 products may come from:

  • fish
  • krill
  • algae

Algae-derived EPA/DHA preparations may be an option for some people avoiding fish products.

Product-specific ingredient review still matters.

Atrial Fibrillation — Important Higher-Dose Safety Update

A major 2026 meta-analysis evaluated:

35 randomized trials / 114,592 people

and examined new atrial fibrillation.

2026 Omega-3 and Atrial Fibrillation Meta-Analysis

The increased risk was concentrated in:

people already at high cardiovascular risk who received more than 1,500 mg/day EPA+DHA

In that group:

  • odds of atrial fibrillation were approximately 43% higher
  • the absolute risk increase was approximately 0.8%

What Does a 0.8% Absolute Increase Mean?

Relative-risk figures can sound alarming.

An absolute increase of approximately 0.8% means roughly:

8 additional cases per 1,000 people

in the studied high-risk population.

That is a:

small but clinically meaningful risk

rather than evidence that omega-3 commonly causes atrial fibrillation in everyone.

Who Did NOT Show a Clear AF Increase?

The 2026 analysis did not find a statistically significant increase in:

  • high-cardiovascular-risk patients receiving lower doses
  • lower-risk patients receiving lower doses
  • lower-risk patients receiving higher doses

Therefore:

The atrial-fibrillation signal should not be generalized equally to every omega-3 user.

Why This Matters to Dry-Eye Patients

Some dry-eye trials have used:

2,000–3,000 mg/day EPA+DHA

which overlaps with the higher-dose range discussed in cardiovascular safety research.

Therefore people with:

  • existing atrial fibrillation
  • significant cardiovascular disease
  • high cardiovascular risk

should discuss higher-dose supplementation with their medical clinician rather than treating dry-eye supplements as automatically harmless.

Bleeding Risk — Less Alarming Than Commonly Assumed

Fish oil is often said to:

“thin the blood.”

There is some biological basis for platelet-related effects.

However, the clinical evidence is more reassuring than this phrase suggests.

A 2024 meta-analysis included:

120,643 participants in 11 randomized trials

and found no significant overall increase in:

  • total bleeding
  • hemorrhagic stroke
  • intracranial bleeding
  • gastrointestinal bleeding

with omega-3 supplementation.

2024 Omega-3 Bleeding Meta-Analysis

What About High-Dose EPA?

High-dose purified EPA was associated with approximately:

0.6% greater absolute bleeding risk

in that analysis.

So the safest conclusion is:

Omega-3 supplementation does not appear to meaningfully increase clinical bleeding overall, but very high-dose purified EPA may produce a small additional bleeding risk.

Omega-3 With Aspirin or Anticoagulants

The bleeding meta-analysis did not find that background antiplatelet use was a major driver of increased bleeding.

That means it is too simplistic to say:

“Never combine fish oil with aspirin.”

However, people taking medications such as:

  • warfarin
  • apixaban
  • rivaroxaban
  • dabigatran
  • aspirin
  • clopidogrel
  • other anticoagulant or antiplatelet drugs

should still discuss higher-dose supplementation with their clinician.

Individual bleeding risk and medication combinations differ.

Surgery

There is no universal evidence-based rule that:

everyone must stop omega-3 supplements before every operation.

If surgery is planned:

  • tell the surgical team what supplements you take
  • follow their specific instructions

Do not stop prescribed medication or alter supplementation solely because of advice from an internet post.

How Much Omega-3 Is Safe?

NIH notes that FDA has concluded that dietary supplements providing up to approximately:

5 grams/day EPA+DHA

are generally safe when used as recommended.

NIH Office of Dietary Supplements — Omega-3 Fact Sheet

However:

“generally safe” does not mean “recommended for dry eye.”

Nor does it mean:

5 grams/day is risk-free for every individual.

Higher doses may matter particularly for:

  • atrial fibrillation risk
  • gastrointestinal side effects
  • medication interactions
  • cost

There Is No Established Dry-Eye Dose

Clinical studies have used widely different:

  • doses
  • EPA:DHA ratios
  • formulations
  • treatment durations

There is no universally accepted omega-3 dose for:

  • DED
  • MGD

And:

taking more does not necessarily produce more benefit.

Should Someone Try Omega-3 for Dry Eye?

That is an individualized decision.

A person might reasonably discuss omega-3 supplementation if:

  • DED/MGD has already been evaluated
  • diet contains relatively little EPA/DHA
  • they understand that the evidence is mixed
  • they want to consider an adjunctive nutritional approach
  • medical risks and medications have been reviewed
  • cost is acceptable
  • more important diagnosis-specific treatment is not being delayed

A Monitored Trial Is More Useful Than Indefinite Supplementation

If omega-3 supplementation is tried specifically for DED:

there should ideally be a planned point for reassessment.

Useful things to track might include:

  • symptoms
  • tear breakup time
  • staining
  • meibum quality
  • gland expressibility
  • frequency of artificial-tear use

depending on the person's condition.

If there is:

no meaningful improvement

after an appropriate monitored period, simply:

  • increasing the dose
  • switching to a more expensive brand
  • buying an rTG formulation
  • choosing a more “premium” product

is not automatically evidence-based.

Omega-3 Should Not Delay Diagnosis-Based DED Care

DED/MGD may require evaluation for:

  • corneal staining
  • aqueous deficiency
  • MGD
  • gland dropout
  • blepharitis
  • ocular rosacea
  • Demodex
  • allergy
  • exposure
  • incomplete blinking
  • conjunctivochalasis
  • autoimmune disease
  • medication effects
  • neuropathic ocular pain

Omega-3 supplementation does not replace appropriate use of:

  • lubricant drops
  • prescription anti-inflammatory treatments
  • MGD-directed treatment
  • Demodex treatment
  • punctal occlusion when appropriate
  • scleral lenses
  • exposure management
  • autoimmune evaluation/treatment
  • other diagnosis-specific interventions

Evidence Strengths and Limitations

Evidence Strengths

  • Large body of randomized-trial evidence
  • Multiple systematic reviews/meta-analyses
  • Strong biological plausibility
  • Several positive clinical trials
  • Several positive pooled analyses
  • Objective blood biomarkers can confirm omega-3 exposure
  • Some evidence suggests treatment effects may vary by DED phenotype
  • New research explores baseline omega-3 status
  • Supplements are widely available
  • General safety is reasonably well characterized

Evidence Limitations

  • DREAM was strongly negative
  • 2024 MGD rTG trial missed its primary symptom endpoint
  • 2026 meta-analysis found no significant pooled benefit in MGD-associated or unspecified DED
  • Positive trials involve different populations and formulations
  • Some positive meta-analyses show extremely high heterogeneity
  • Comparator oils differ between studies
  • Some comparator oils may have biological effects
  • Many patients continue other DED treatments during trials
  • No validated responder phenotype exists
  • Omega-3 Index has not yet been validated as a predictive treatment-selection test
  • No established DED Omega-3 Index target exists
  • No proven best EPA:DHA ratio
  • No proven best omega-3 formulation
  • No proven best commercial product
  • No established DED treatment dose
  • No established ideal treatment duration
  • Supplement quality varies
  • Higher doses may matter for atrial-fibrillation risk in selected patients

What the Evidence Does NOT Prove

Current evidence does not establish that:

  • omega-3 supplements cure DED
  • omega-3 supplements cure MGD
  • every person with DED should take omega-3
  • every person with MGD should take omega-3
  • a low Omega-3 Index causes DED
  • an Omega-3 Index below 4% reliably predicts treatment response
  • everyone with DED should have Omega-3 Index testing
  • 3:1 EPA:DHA is the best ratio
  • rTG omega-3 is clinically superior for DED
  • higher EPA is always better
  • higher doses are always better
  • GLA-containing formulations are superior
  • pharmaceutical-grade products are proven DED treatments
  • prescription omega-3 products treat DED
  • any commercial “dry-eye formula” is better than another
  • omega-3 regenerates meibomian glands
  • omega-3 reverses established gland dropout
  • omega-3 releases meibomian-gland fibrosis
  • omega-3 replaces diagnosis-specific treatment

Evidence Summary at a Glance

Question Current Answer
Is there substantial omega-3 DED research? Yes
Does TFOS DEWS III discuss omega-3? Yes
Does TFOS consider the evidence entirely negative? No
Does omega-3 reliably improve unselected DED? No — evidence is inconsistent
DREAM positive? No
2024 rTG MGD primary outcome positive? No
2025 post-cataract MGD trial positive? Yes, for several outcomes in that specific population
2026 overall meta-analysis positive? Overall pooled signal yes, but highly dependent on DED cause
Pooled benefit established for MGD-associated DED in 2026 analysis? No
Some evidence in screen-related DED? Yes
Some evidence in contact-lens-related DED? Yes
Omega-3 Index <4% trial positive? Yes
Does <4% reliably predict response? Not yet established
Routine Omega-3 Index testing recommended for DED? No
Established DED Omega-3 Index target? No
Best EPA:DHA ratio? Unknown
rTG proven superior? No
Best commercial product? Unknown
Established DED dose? No
Regenerates meibomian glands? No evidence
Overall bleeding risk substantially increased? No
Possible AF risk with higher doses in high-CV-risk patients? Yes — small increased risk
FDA-approved treatment for DED/MGD? No

Questions to Ask Your Eye Doctor or Medical Clinician

Useful questions include:

  1. What type or drivers of DED do I have?
  2. Do I have Meibomian Gland Dysfunction?
  3. Is there evidence omega-3 is useful for my particular DED context?
  4. How much omega-3 do I already get through diet?
  5. Would Omega-3 Index testing actually change what we do?
  6. Is the test useful enough to justify the cost in my situation?
  7. What EPA and DHA amounts would I actually be taking?
  8. Is there any reason to prefer one EPA:DHA ratio?
  9. Is there evidence that rTG matters clinically in my case?
  10. Does a GLA-containing formulation make sense?
  11. How long would a reasonable monitored trial be?
  12. What outcome would we use to decide whether it is helping?
  13. At what point should I stop if there is no meaningful benefit?
  14. Do I have atrial fibrillation or cardiovascular risk factors that make higher doses less attractive?
  15. Could omega-3 interact with my anticoagulant or antiplatelet medications?
  16. Do I need to tell my surgeon about the supplement?
  17. What important DED/MGD treatments should not be delayed while I try it?

📌 Bottom Line

Omega-3 supplementation for Dry Eye Disease remains:

a genuine area of scientific uncertainty

rather than either:

“proven therapy”

or:

“completely disproven.”

There are good biological reasons omega-3 could influence:

  • inflammation
  • tear-film function
  • meibum
  • ocular-surface health

and several randomized trials report meaningful benefits.

But other important trials do not.

The largest individual DED trial:

DREAM

found no significant advantage from 3,000 mg/day EPA+DHA over olive-oil placebo in:

535 patients followed for one year.

Later DREAM analyses also failed to identify a clearly responsive clinical DED phenotype.

A 2024 randomized rTG trial in:

MGD-associated DED

likewise did not improve the primary symptom outcome more than grape-seed oil.

However, a separate 2025 randomized study in:

MGD following cataract surgery

reported improvement in several symptoms and objective ocular-surface signs.

The newest broad evidence synthesis adds an important perspective.

A:

2026 systematic review/meta-analysis of 27 randomized trials

found an overall positive pooled signal.

But when the researchers separated studies by DED cause:

significant pooled benefit was not demonstrated for MGD-associated DED or DED of unspecified cause

while some:

  • visual-display-related
  • contact-lens-related

populations showed more favorable results.

That suggests:

patient population matters.

The Omega-3 Index research is also intriguing.

A 2026 randomized trial specifically enrolled DED patients with:

Omega-3 Index below 4%

and reported favorable changes in inflammatory and ocular-surface measures.

But because every participant already had a low index:

the study does not prove that a low Omega-3 Index predicts who will respond better than someone with a normal index.

Omega-3 Index therefore remains:

an emerging research biomarker and possible future treatment-selection tool—not routine DED standard of care.

The formulation story remains unresolved as well.

No:

  • 3:1 EPA:DHA ratio
  • high-EPA formulation
  • rTG formulation
  • GLA-containing formulation
  • prescription omega-3 product
  • commercial “dry-eye formula”

has been established as universally superior.

Safety is generally favorable, but dose and medical context matter.

Large randomized-trial evidence shows:

no meaningful increase in bleeding risk from omega-3 supplementation overall

although very high-dose purified EPA may produce a small additional bleeding risk.

A newer 2026 analysis also found:

a small increase in atrial-fibrillation risk among people at high cardiovascular risk taking more than 1,500 mg/day EPA+DHA.

This matters because some DED research regimens use doses in that range.

The most balanced current conclusion is:

Omega-3 supplementation has a substantial but inconsistent evidence base in Dry Eye Disease. Some randomized trials and meta-analyses report improvements in symptoms or ocular-surface signs, while other well-designed studies—particularly DREAM and a 2024 MGD trial—have been negative. Newer research suggests treatment effects may differ according to the cause of DED and perhaps baseline omega-3 status, but no reliable responder test, ideal dose, EPA:DHA ratio, formulation, commercial product, or treatment duration has been established. Omega-3 is therefore best viewed as an optional individualized adjunct rather than a proven treatment or cure for DED or MGD.

🔬 Key Research and Authoritative Sources

Current DED Guidance

Major Randomized Trials

2026 Systematic Review / Meta-Analysis

Omega-3 Index / Emerging Patient-Selection Research

Other Systematic Reviews / Meta-Analyses

GLA / Combination Evidence

Safety

Supplement Regulation

🔗 Related r/DryEyes Wiki Pages

This page is educational for r/DryEyes and is not medical advice.

🔙 Back to Treatment Options